A Phase 1/2 interventional study of VIR-2218 and Placebo in Chronic Hepatitis B, sponsored by Vir Biotechnology, Inc.. Completed at 14 sites in 5 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-13.
Sponsored by Vir Biotechnology, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Hepatitis B, Chronic with a site in Thailand — 3 open to participants now, 3 under way, none of them phase 3. Hepatitis B, Chronic · Thailand.
Among the 51 studies in Hepatitis B, Chronic with a site in Thailand, this one is the 31st largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2018, is one of 5 in phase 1/2, and was the 28th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 51 studies in Hepatitis B, Chronic with a site in Thailand are open now. Recruiting first, the newest first:
Institut de Recherche pour le Developpement · Sites in Thailand
Ages 15+ · Healthy volunteers
Siriraj Hospital · Sites in Thailand
Ages 18+
The Task Force for Global Health · Sites in Thailand
Healthy volunteers
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 11 · Phase 4 5
First in 2002; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 126 across the 41 interventional studies, 1,655 across the 8 observational. Of the 43 that completed or were terminated, 22 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 51 have an industry lead sponsor. The 10 most frequent:
Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Vir Biotechnology, Inc. has 5 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 51 studies in Hepatitis B, Chronic with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 1/2 study in which healthy adult subjects and subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 or placebo and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity (only in subjects with chronic HBV).
In the single ascending dose (SAD) part, Part A, healthy adult subjects will receive one dose of VIR-2218 or placebo, administered subcutaneously (SC). In the multiple ascending dose (MAD) parts, Part B \& Part C, subjects with chronic HBV infection will receive two doses of VIR-2218 or placebo every 4 weeks administered SC.
Part A SAD:
Inclusion Criteria:
Exclusion Criteria:
Parts B/C MAD:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
Drug: VIR-2218
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
Drug: VIR-2218
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
Drug: VIR-2218
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
Drug: VIR-2218
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
Drug: VIR-2218
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
Drug: VIR-2218
Healthy subjects received a single dose of placebo administered SC
Drug: Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart.
Drug: VIR-2218
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
Drug: VIR-2218
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
Drug: VIR-2218
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
Drug: VIR-2218
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
Drug: VIR-2218
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
Drug: VIR-2218
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Drug: Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Drug: Placebo
VIR-2218 given by subcutaneous injection
Sterile normal saline (0.9% NaCl) given by subcutaneous injection
Incidence of Adverse Events (AEs)
Number of Subjects with Adverse Events as assessed by CTCAE v5.0. In our planned analysis for this outcome measure, incidence is defined as the number of participants with treatment emergent AEs (TEAEs) in relation to the total number of participants in the cohort.
Time frame: Up to 364 days
Clinical Assessments Including But Not Limited to Laboratory Test Results
Number of participants with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.
Time frame: Up to 336 days
Maximum Plasma Concentration (ng/mL)
VIR-2218 and metabolite Maximum Concentration in Plasma
Time frame: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose and Week 1; Part B/C: predose on Day 1 and at 1h, 2h, 4h, 8h, 24h postdose, Week 1, predose on Week 4 and at 1h, 2h, 4h, 8h, 24h postdose, and Week 5
Time to Reach Maximum Plasma Concentration (h)
VIR-2218 and metabolite time of Cmax in Plasma: Median (Inter-Quartile Range Q1-Q3)
Time frame: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose and Week 1; Part B/C: predose on Day 1 and at 1h, 2h, 4h, 8h, 24h postdose, Week 1, predose on Week 4 and at 1h, 2h, 4h, 8h, 24h postdose, and Week 5
Area Under the Plasma Concentration Versus Time Curve (ng*h/mL)
VIR-2218 and metabolite Area under the curve from time 0 to last measurable Time
Time frame: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose and Week 1; Part B/C: predose on Day 1 and at 1h, 2h, 4h, 8h, 24h postdose, Week 1, predose on Week 4 and at 1h, 2h, 4h, 8h, 24h postdose, and Week 5
Apparent Terminal Elimination Half-life (h)
VIR-2218 Apparent Elimination Half-life t1/2 in Plasma: Median (Inter-Quartile Range Q1-Q3)
Time frame: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose and Week 1
Apparent Plasma Clearance (L/h)
VIR-2218 CL/F Apparent plasma clearance
Time frame: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose, and Week 1
Apparent Volume of Distribution (L)
VIR-2218 VZ/F apparent volume of distribution
Time frame: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose, and Week 1
Urine %fe 0-24h
VIR-2218 and metabolite: Fraction excreted in the urine from time 0 to 24 h. Pooled Urine PK samples was collected at pre-specified intervals in the single ascending dose study of VIR-2218. Therefore, the following PK parameter, fraction excreted in the urine ( %fe 0-24h ) was only calculated in healthy subjects who participated in Part A of the study. This parameter was not listed as a secondary endpoint for parts B/C in the submitted protocol, and as such was not reported in this secondary outcome measures.
Time frame: Pooled urine was collected at time interval D1 (0-4 hrs) (4-8 hrs) (8-12 hrs) and (12-24 hrs)
Apparent Renal Clearance (CLR/F)
VIR-2218 Apparent renal clearance from 0 to 24 h. Pooled Urine PK samples was collected at pre-specified intervals in the single ascending dose study of VIR-2218. Therefore, the following PK parameter, apparent renal clearance (CLR/F) was only calculated in healthy subjects who participated in Part A of the study. This parameter was not listed as a secondary endpoint for parts B/C in the submitted protocol, and as such was not reported in this secondary outcome measures.
Time frame: Pooled Urine was collected at time interval D1 (0-4 hrs) (4-8 hrs) (8-12 hrs) and (12-24 hrs)
Maximum Reduction of Serum HBsAg From Baseline
Maximum reduction of serum HBsAg from Day 1 until Week 16.
Time frame: Up to 112 days
Number of Subjects With Serum HBsAg Loss at Any Time Point
Serum HBsAg loss is defined as quantitative HBsAg \< 0.05 IU/mL at two or more consecutive measurements
Time frame: Up to 336 days
Number of Subjects With Sustained Serum HBsAg Loss for >/= 6 Months
Serum HBsAg loss is defined as quantitative HBsAg \< 0.05 IU/mL at two or more consecutive measurements
Time frame: Up to 336 days
Number of Subjects With Anti-HBs Seroconversion at Any Timepoint
Anti-HBs seroconversion is defined as anti-HBs positivity at two or more consecutive measurements
Time frame: Up to 336 days
Number of Subjects With HBeAg Loss and/or Anti-HBe Seroconversion at Any Timepoint
HBeAg loss is defined as quantitative HBeAg \< 0.11 IU/mL at two or more consecutive measurements. anti-HBe seroconversion is defined as anti-HBe positivity at two or more consecutive measurements
Time frame: Up to 336 days
| Milestone | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD 200 mg | Part B: MAD Placebo | Part C: MAD Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 8 | 6 | 6 | 12 | 3 | 6 | 6 | 3 | 3 | 3 | 6 | 2 |
| Dosed | 6 | 6 | 6 | 7 | 6 | 6 | 12 | 3 | 6 | 6 | 3 | 3 | 3 | 6 | 2 |
| Completed | 6 | 6 | 5 | 5 | 6 | 6 | 12 | 3 | 6 | 6 | 3 | 3 | 2 | 6 | 2 |
| Not completed | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of Subjects with Adverse Events as assessed by CTCAE v5.0. In our planned analysis for this outcome measure, incidence is defined as the number of participants with treatment emergent AEs (TEAEs) in relation to the total number of participants in the cohort.
| Participants | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2219 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence of Adverse Events (AEs) | 4 | 3 | 4 | 5 | 3 | 3 | 6 | 0 | 2 | 5 | 2 | 2 | 2 | 1 | 1 |
Number of participants with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.
| Participants | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTCAE v5.0 Lab Grade 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| CTCAE v5.0 Lab Grade 1 | 3 | 3 | 3 | 4 | 4 | 3 | 7 | 2 | 4 | 5 | 3 | 3 | 3 | 3 | 2 |
| CTCAE v5.0 Lab Grade 2 | 1 | 2 | 1 | 1 | 1 | 3 | 3 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 0 |
| CTCAE v5.0 Lab Grade 3 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CTCAE v5.0 Lab Grade 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Clinically Significant Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Clinically Significant ECG | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VIR-2218 and metabolite Maximum Concentration in Plasma
| ng/mL | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part B/C: MAD VIR-2218 20 mg | Part B/C: MAD VIR-2218 50 mg | Part B/C: MAD VIR-2218 100 mg | Parts B/C: MAD VIR-2218 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| VIR-2218 Cmax (Day 1) | 155 ± 65.3 | 355 ± 117 | 711 ± 207 | 2110 ± 722 | 1830 ± 615 | 5010 ± 630 | 73.5 ± NA | 118 ± 61.2 | 235 ± 79.0 | 826 ± 336 |
| AS (N-1)3' VIR-2218 Cmax (Day 1) | NA ± NA | 40.5 ± NA | 62.4 ± 17.6 | 259 ± 114 | 177 ± 99.2 | 514 ± 106 | NA ± NA | NA ± NA | NA ± NA | 66.1 ± NA |
| VIR-2218 Cmax (Day 29) | — | — | — | — | — | — | 51.8 ± 21.1 | 115 ± 38.2 | 256 ± 167 | 807 ± 374 |
| AS (N-1)3' VIR-2218 Cmax (Day 29) | — | — | — | — | — | — | NA ± NA | NA ± NA | NA ± NA | 75.1 ± 27.2 |
VIR-2218 and metabolite time of Cmax in Plasma: Median (Inter-Quartile Range Q1-Q3)
| h | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part B/C: MAD VIR-2218 20 mg | Part B/C: MAD VIR-2218 50 mg | Part B/C: MAD VIR-2218 100 mg | Part B/C: MAD VIR-2218 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| VIR-2218 Tmax Day 1 | 4.25 (1.17 to 4.25) | 4.32 (4.25 to 6.17) | 5.21 (4.25 to 6.18) | 7.21 (4.25 to 8.25) | 7.21 (6.17 to 10.2) | 4.25 (4.25 to 8.25) | 4.00 (4.00 to 8.02) | 7.63 (4.00 to 7.93) | 2.48 (1.00 to 7.97) | 5.98 (3.98 to 8.00) |
| AS(N-1)3' VIR-2218 Tmax Day 1 | NA (NA to NA) | 6.17 (4.25 to 6.17) | 6.17 (4.25 to 6.18) | 9.21 (4.25 to 10.2) | 10.2 (8.25 to 10.2) | 8.25 (4.25 to 10.2) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 8.00 (7.97 to 8.00) |
| VIR-2218 Tmax Day 29 | — | — | — | — | — | — | 3.95 (0.92 to 4.00) | 4.00 (4.00 to 7.98) | 8.00 (4.00 to 8.00) | 3.99 (2.00 to 8.00) |
| AS (N-1)3' VIR-2218 Tmax Day 29 | — | — | — | — | — | — | NA (NA to NA) | NA (NA to NA) | 6.00 (4.00 to 8.00) | 5.99 (4.00 to 8.00) |
VIR-2218 and metabolite Area under the curve from time 0 to last measurable Time
| h*ng/mL | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part B/C: MAD VIR-2218 20mg | Part B/C: MAD VIR-2218 50 mg | Part B/C: MAD VIR-2218 100 mg | Part B/C: MAD VIR-2218 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| VIR-2218 AUClast (Day 1) | 1270 ± 270 | 3740 ± 1190 | 6630 ± 1160 | 23500 ± 2700 | 27900 ± 7540 | 58800 ± 9070 | 360 ± 199 | 1000 ± 285 | 2700 ± 943 | 9570 ± 2410 |
| AS(N-1) 3' VIR-2218 AUClast (Day 1) | NA ± NA | 208 ± 190 | 481 ± 149 | 2530 ± 613 | 2680 ± 1460 | 6430 ± 1500 | NA ± NA | NA ± NA | NA ± NA | 482 ± 199 |
| VIR-2218 AUClast (Day 29) | — | — | — | — | — | — | 339 ± 171 | 910 ± 326 | 2550 ± 638 | 9580 ± 3240 |
| AS(N-1) 3' VIR-2218AUClast (Day 29) | — | — | — | — | — | — | NA ± NA | NA ± NA | 174 ± NA | 393 ± 230 |
VIR-2218 Apparent Elimination Half-life t1/2 in Plasma: Median (Inter-Quartile Range Q1-Q3)
| h | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg |
|---|---|---|---|---|---|---|
| Apparent Terminal Elimination Half-life (h) | 2.45 (2.35 to 3.26) | 3.64 (3.49 to 4.95) | 4.38 (4.22 to 6.11) | 3.54 (2.49 to 5.51) | 5.28 (5.12 to 5.62) | 4.55 (3.25 to 4.69) |
VIR-2218 CL/F Apparent plasma clearance
| L/h | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg |
|---|---|---|---|---|---|---|
| Apparent Plasma Clearance (L/h) | 34.0 ± 2.54 | 21.8 ± 4.27 | 30.8 ± 4.51 | 16.8 ± 1.76 | 21.9 ± 6.91 | 15.3 ± 2.08 |
VIR-2218 VZ/F apparent volume of distribution
| L | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg |
|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (L) | 155 ± 69.7 | 132 ± 40.7 | 223 ± 76.0 | 104 ± 62.6 | 176 ± 60.8 | 92.9 ± 24.6 |
VIR-2218 and metabolite: Fraction excreted in the urine from time 0 to 24 h. Pooled Urine PK samples was collected at pre-specified intervals in the single ascending dose study of VIR-2218. Therefore, the following PK parameter, fraction excreted in the urine ( %fe 0-24h ) was only calculated in healthy subjects who participated in Part A of the study. This parameter was not listed as a secondary endpoint for parts B/C in the submitted protocol, and as such was not reported in this secondary outcome measures.
| % excreted in the urine from time 0-24h | Part A SAD: VIR-2218 50 mg | Part A SAD: VIR-2218 100 mg | Part A SAD: VIR-2218 200 mg | Part A SAD: VIR-2218 400 mg | Part A SAD: VIR-2218 600 mg | Part A SAD: VIR-2218 900 mg |
|---|---|---|---|---|---|---|
| VIR-2218 fe 0-24 | 16.9 ± 3.19 | 21.7 ± 6.22 | 23.2 ± 4.34 | 29.5 ± 5.72 | 32.3 ± 11.7 | 47.6 ± 8.59 |
| AS(N-1)3' VIR-2218 fe 0-24 | 1.94 ± 0.480 | 4.16 ± 2.28 | 3.31 ± 0.656 | 4.99 ± 0.740 | 4.12 ± 2.31 | 6.96 ± 1.47 |
VIR-2218 Apparent renal clearance from 0 to 24 h. Pooled Urine PK samples was collected at pre-specified intervals in the single ascending dose study of VIR-2218. Therefore, the following PK parameter, apparent renal clearance (CLR/F) was only calculated in healthy subjects who participated in Part A of the study. This parameter was not listed as a secondary endpoint for parts B/C in the submitted protocol, and as such was not reported in this secondary outcome measures.
| L/h | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg |
|---|---|---|---|---|---|---|
| Apparent Renal Clearance (CLR/F) | 5.87 ± 0.728 | 5.22 ± 1.27 | 7.00 ± 0.659 | 5.13 ± 0.850 | 7.22 ± 1.480 | 7.47 ± 1.340 |
Maximum reduction of serum HBsAg from Day 1 until Week 16.
| log10 IU/mL | Part B MAD: VIR-2218 20 mg | Part B MAD: VIR-2218 50 mg | Part B MAD: VIR-2218 100 mg | Part B MAD: VIR-2218 200 mg | Part C MAD: VIR-2218 50 mg | Part C MAD: VIR-2218 200 mg | Part B MAD: Placebo | Part C MAD: Placebo |
|---|---|---|---|---|---|---|---|---|
| Maximum Reduction of Serum HBsAg From Baseline | -1.031 ± 0.574 | -1.230 ± 0.702 | -1.504 ± 0.540 | -1.653 ± 0.154 | -1.161 ± 0.350 | -1.568 ± 0.636 | -0.098 ± 0.047 | -0.068 ± 0.01 |
Serum HBsAg loss is defined as quantitative HBsAg \< 0.05 IU/mL at two or more consecutive measurements
| Participants | Part B MAD: VIR-2218 20 mg | Part B MAD: VIR-2218 50 mg | Part B MAD: VIR-2218 100 mg | Part B MAD: VIR-2218 200 mg | Part C MAD: VIR-2218 50 mg | Part C MAD: VIR-2218 200 mg | Part B MAD: Placebo | Part C MAD: Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Serum HBsAg Loss at Any Time Point | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serum HBsAg loss is defined as quantitative HBsAg \< 0.05 IU/mL at two or more consecutive measurements
| Participants | Part B MAD: VIR-2218 20 mg | Part B MAD: VIR-2218 50 mg | Part B MAD: VIR-2218 100 mg | Part B MAD: VIR-2218 200 mg | Part C MAD: VIR-2218 50 mg | Part C MAD: VIR-2218 200 mg | Part B MAD: Placebo | Part C MAD: Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Sustained Serum HBsAg Loss for >/= 6 Months | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Anti-HBs seroconversion is defined as anti-HBs positivity at two or more consecutive measurements
| Participants | Part B MAD: VIR-2218 20 mg | Part B MAD: VIR-2218 50 mg | Part B MAD: VIR-2218 100 mg | Part B MAD: VIR-2218 200 mg | Part C MAD: VIR-2218 50 mg | Part C MAD: VIR-2218 200 mg | Part B MAD: Placebo | Part C MAD: Placebo |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Anti-HBs Seroconversion at Any Timepoint | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HBeAg loss is defined as quantitative HBeAg \< 0.11 IU/mL at two or more consecutive measurements. anti-HBe seroconversion is defined as anti-HBe positivity at two or more consecutive measurements
| Participants | Part C MAD: VIR-2218 50 mg | Part C MAD: VIR-2218 200 mg | Part C MAD: Placebo |
|---|---|---|---|
| Number of Subjects with HBeAg Loss | 0 | 1 | 0 |
| Number of Subjects with anti-HBe seroconversion | 0 | 1 | 0 |
Collected over Up to 364 days after first dose with VIR-2218 or placebo. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A SAD: VIR-2218 50 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A SAD: VIR-2218 100 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A SAD: VIR-2218 200 mg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A SAD: VIR-2218 400 mg | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Part A SAD: VIR-2218 600 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A SAD: VIR-2218 900 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A SAD: Placebo | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Part B MAD: VIR-2218 20 mg | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Part B MAD: VIR-2218 50 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part B MAD: VIR-2218 100 mg | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Part B MAD: VIR-2218 200 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part C MAD: VIR-2218 50 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part C MAD: VIR-2218 200 mg | 1/3 (33.3%) | 0/3 (0%) | 2/3 (66.7%) |
| Part B MAD: Placebo | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part C MAD: Placebo | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Event | Part A SAD: VIR-2218 50 mg | Part A SAD: VIR-2218 100 mg | Part A SAD: VIR-2218 200 mg | Part A SAD: VIR-2218 400 mg | Part A SAD: VIR-2218 600 mg | Part A SAD: VIR-2218 900 mg | Part A SAD: Placebo | Part B MAD: VIR-2218 20 mg | Part B MAD: VIR-2218 50 mg | Part B MAD: VIR-2218 100 mg | Part B MAD: VIR-2218 200 mg | Part C MAD: VIR-2218 50 mg | Part C MAD: VIR-2218 200 mg | Part B MAD: Placebo | Part C MAD: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/12 | 0/3 | 0/6 | 1/6 | 0/3 | 0/3 | 0/3 | 0/6 | 0/2 |
| Event | Part A SAD: VIR-2218 50 mg | Part A SAD: VIR-2218 100 mg | Part A SAD: VIR-2218 200 mg | Part A SAD: VIR-2218 400 mg | Part A SAD: VIR-2218 600 mg | Part A SAD: VIR-2218 900 mg | Part A SAD: Placebo | Part B MAD: VIR-2218 20 mg | Part B MAD: VIR-2218 50 mg | Part B MAD: VIR-2218 100 mg | Part B MAD: VIR-2218 200 mg | Part C MAD: VIR-2218 50 mg | Part C MAD: VIR-2218 200 mg | Part B MAD: Placebo | Part C MAD: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac murmurInvestigations | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/12 | 0/3 | 0/6 | 0/6 | 0/3 | 0/3 | 0/3 | 0/6 | 1/2 |
| HeadacheNervous system disorders | 1/6 | 3/6 | 2/6 | 2/7 | 0/6 | 1/6 | 2/12 | 0/3 | 1/6 | 2/6 | 1/3 | 1/3 | 1/3 | 0/6 | 0/2 |
| PalpitationsCardiac disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/12 | 0/3 | 0/6 | 0/6 | 0/3 | 1/3 | 0/3 | 0/6 | 0/2 |
| ToothacheGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/12 | 0/3 | 0/6 | 0/6 | 1/3 | 0/3 | 0/3 | 0/6 | 0/2 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/12 | 0/3 | 0/6 | 2/6 | 0/3 | 0/3 | 0/3 | 0/6 | 0/2 |
| Influenza like illnessGeneral disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/12 | 0/3 | 0/6 | 0/6 | 0/3 | 0/3 | 1/3 | 0/6 | 0/2 |
| Injection site bruisingGeneral disorders | 0/6 | 0/6 | 0/6 | 0/7 | 1/6 | 2/6 | 0/12 | 0/3 | 0/6 | 0/6 | 0/3 | 1/3 | 0/3 | 0/6 | 0/2 |
| ContusionInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 1/6 | 0/12 | 0/3 | 0/6 | 0/6 | 0/3 | 1/3 | 0/3 | 0/6 | 0/2 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/12 | 0/3 | 0/6 | 1/6 | 0/3 | 0/3 | 1/3 | 0/6 | 0/2 |
| DizzinessNervous system disorders | 0/6 | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 1/12 | 0/3 | 0/6 | 2/6 | 0/3 | 0/3 | 0/3 | 0/6 | 0/2 |
The Overall Number of Baseline Participants is not consistent with numbers provided in the rows of the Participant Flow module because we enrolled and randomized 8 participants for the Part A 400 mg cohort, but only 7 of these participants were dosed and included for full analysis dataset. We have added a row for dosed participants in the Participant Flow module, to clarify this inconsistency and reflect the number of participants in the analysis dataset.
| Age, Continuous(Years) | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 25 ± 3 | 23.3 ± 4 | 26.7 ± 3.8 | 24.3 ± 3.7 | 28.8 ± 6.3 | 32.5 ± 9.5 | 26.5 ± 6.7 | 40.3 ± 9.1 | 42.5 ± 10.8 | 45.2 ± 5.5 | 55 ± 4 | 35 ± 9.8 | 33.7 ± 13.1 | 44 ± 7.2 | 58.5 ± 7.8 | 33.4 ± 11.5 |
| Sex: Female, Male(Participants) | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 4 | 3 | 7 | 3 | 3 | 5 | 1 | 1 | 1 | 3 | 2 | 1 | 3 | 1 | 44 |
| Male | 0 | 2 | 3 | 0 | 3 | 3 | 7 | 2 | 5 | 5 | 0 | 1 | 2 | 3 | 1 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 6 | 6 | 6 | 7 | 6 | 5 | 11 | 3 | 6 | 6 | 3 | 3 | 3 | 6 | 2 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 3 | 0 | 0 | 2 | 1 | 1 | 3 | 5 | 5 | 3 | 3 | 3 | 6 | 2 | 39 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 2 | 5 | 5 | 3 | 3 | 8 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Region of Enrollment(participants) | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| New Zealand | 6 | 6 | 6 | 7 | 6 | 6 | 12 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 54 |
| South Korea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 0 | 8 |
| Hong Kong | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 1 | 1 | 2 | 0 | 8 |
| Australia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 4 |
| Thailand | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 3 | 1 | 7 |
| Hepatitis B Surface Antigen Levels (IU/mL)(IU/mL) | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | — | — | — | 2372.227 ± 1168.940 | 3872.625 ± 5678.292 | 4009.863 ± 5239.703 | 2374.423 ± 2078.034 | 3488.037 ± 2454.215 | 12640.983 ± 10495.983 | 4819.127 ± 6348.594 | 1886.045 ± 1223.655 | 4456.52 ± 5657.74 |
| Alanine Aminotransferase Levels(U/L) | Part A: SAD VIR-2218 50 mg | Part A: SAD VIR-2218 100 mg | Part A: SAD VIR-2218 200 mg | Part A: SAD VIR-2218 400 mg | Part A: SAD VIR-2218 600 mg | Part A: SAD VIR-2218 900 mg | Part A: SAD Placebo | Part B: MAD VIR-2218 20 mg | Part B: MAD VIR-2218 50 mg | Part B: MAD VIR-2218 100 mg | Part B: MAD VIR-2218 200 mg | Part C: MAD VIR-2218 50 mg | Part C: MAD VIR-2218 200 mg | Part B: MAD Placebo | Part C: MAD Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | — | — | — | 15.3 ± 4.6 | 23.5 ± 14.9 | 14.3 ± 5.0 | 10.0 ± 4.0 | 27.7 ± 18.6 | 26.0 ± 17.7 | 21.8 ± 17.6 | 26.5 ± 10.6 | 20.25 ± 13.08 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Sep 2020, 21 months.
Results were first posted in Dec 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elebsiran